Acyl-carnitines in a therapeutical method for treating chronic u

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424312, 424313, 424314, 424316, A61K 3132

Patent

active

042371678

ABSTRACT:
A therapeutical method for treating uraemic patients in regular dialysis treatment (RDT) is disclosed, wherein an acyl-carnitine (typically acetyl-carnitine) is administered to the patients. The acyl-carnitine can be administered over the whole treatment period by the oral route exclusively. Alternatively, while oral administration is carried out in those days in which the patient is not subjected to the haemodialytic session, when the patient undergoes dialysis, the acyl-carnitine is administered by slow infusion, or an acyl-carnitine-containing dialyzing liquid is used. Furthermore, a suitable dialyzing solution is also disclosed.

REFERENCES:
Lancet, Apr. 21, 1979, p. 882.
Chemical Abstracts, 86:137401b, (1977).
Chemical Abstracts, 83:73716m, (1975).
Chemical Abstracts, 82:166032e, (1975).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Acyl-carnitines in a therapeutical method for treating chronic u does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acyl-carnitines in a therapeutical method for treating chronic u, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acyl-carnitines in a therapeutical method for treating chronic u will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2284168

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.